Clinical trials · District of Columbia
Multiple sclerosis clinical trials in District of Columbia
We’re tracking 8 recruiting multiple sclerosis studies with a site in District of Columbia — including Phase 1, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in District of Columbia
- NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
Washington D.C., District of ColumbiaAges 18–55 - NCT07224373RecruitingPhase 1
A study of AZD0120 for multiple sclerosis
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Washington D.C., District of ColumbiaAges 18–60 - NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06441617Recruiting
Online program to reduce fatigue in multiple sclerosis
This trial tests an online self-management program to help reduce fatigue in people with MS. You'll use a website or app over 24 weeks, and researchers will check how well it works.
Washington D.C., District of ColumbiaAges 22 years+ - NCT06846281RecruitingPhase 3
Switching to remibrutinib from ocrelizumab for relapsing MS
This study tests a new oral medication called remibrutinib for people with relapsing MS who are currently on ocrelizumab. The goal is to see if switching to remibrutinib is safe and effective for controlling MS long-term.
Washington D.C., District of ColumbiaAges 40–70 - NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Washington D.C., District of ColumbiaAges 18–65 - NCT05877963RecruitingPhase 3
Ublituximab treatment plan for relapsing multiple sclerosis
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Washington D.C., District of ColumbiaAges 18–65 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Washington D.C., District of ColumbiaAges 18 years+
Multiple sclerosis trials by city in District of Columbia
Where these studies are running in District of Columbia
Institutions with a site for the recruiting multiple sclerosis studies listed above.
- MedStar Georgetown University Hospital · 2 studies
- TG Therapeutics Investigational Trial Site · 2 studies
- Children's National Medical Center
- Georgetown University Medical Center
- MedStar Health
- MedStar Washington Hospital Center
- Washington DC VA Medical Center
What taking part in a multiple sclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Multiple sclerosis trials in other states
Common questions
- Are there multiple sclerosis clinical trials in District of Columbia?
- Yes. We're currently tracking 8 recruiting multiple sclerosis studies with a site in District of Columbia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple sclerosis study in District of Columbia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in District of Columbia to take part?
- Not necessarily. These studies have a site in District of Columbia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple sclerosis studies open in District of Columbia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.